logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
ENLV
Enlivex Therapeutics Ltd.
4.66
1 x 4.70
3 x 5.05
bid
ask
-
0.07
1.48%
10:02 AM
timesize
Ytd-55.83%
1y-73.67%
4.57
day range
4.80
4.25
52 week range
31.50
Open4.65Prev Close4.73Low4.57High4.80Mkt Cap79.62M
Vol6.47KAvg Vol38.19KEPS404.50P/E0.01Forward P/E-2.14
Beta1.52Short Ratio0.56Inst. Own18.81%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-3050-d Avg9.36200-d Avg13.561yr Est9.50

ENLV News

Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
defenseworld.net
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report)

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
globenewswire.com
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at

Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "C

Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
zacks.com
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why

Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is ref

Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in over

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
globenewswire.com
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age

Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
globenewswire.com
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
globenewswire.com
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cry

Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the

benzinga.com
Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B

Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
globenewswire.com
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "C

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
globenewswire.com
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Oste

Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
globenewswire.com
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2

As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading instituti

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
globenewswire.com
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation a

The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Phili

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
globenewswire.com
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundat

As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.1

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
globenewswire.com
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In L

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
globenewswire.com
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allo

Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (D

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
globenewswire.com
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Co

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
globenewswire.com
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchan

The listing on one of the world's largest global cryptocurrency exchanges expands market access and

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
globenewswire.com
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Rep

New acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury s

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
globenewswire.com
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
globenewswire.com
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary

· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recen

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

    On Thursday, 105 stocks hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday